Your browser doesn't support javascript.
loading
De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome.
Vetrini, Francesco; McKee, Shane; Rosenfeld, Jill A; Suri, Mohnish; Lewis, Andrea M; Nugent, Kimberly Margaret; Roeder, Elizabeth; Littlejohn, Rebecca O; Holder, Sue; Zhu, Wenmiao; Alaimo, Joseph T; Graham, Brett; Harris, Jill M; Gibson, James B; Pastore, Matthew; McBride, Kim L; Komara, Makanko; Al-Gazali, Lihadh; Al Shamsi, Aisha; Fanning, Elizabeth A; Wierenga, Klaas J; Scott, Daryl A; Ben-Neriah, Ziva; Meiner, Vardiella; Cassuto, Hanoch; Elpeleg, Orly; Holder, J Lloyd; Burrage, Lindsay C; Seaver, Laurie H; Van Maldergem, Lionel; Mahida, Sonal; Soul, Janet S; Marlatt, Margaret; Matyakhina, Ludmila; Vogt, Julie; Gold, June-Anne; Park, Soo-Mi; Varghese, Vinod; Lampe, Anne K; Kumar, Ajith; Lees, Melissa; Holder-Espinasse, Muriel; McConnell, Vivienne; Bernhard, Birgitta; Blair, Ed; Harrison, Victoria; Muzny, Donna M; Gibbs, Richard A; Elsea, Sarah H; Posey, Jennifer E.
Afiliação
  • Vetrini F; Baylor Genetics, Houston, TX, 77021, USA.
  • McKee S; Present address: Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Rosenfeld JA; Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, UK.
  • Suri M; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Lewis AM; Nottingham Genetics Service, Nottingham City Hospital, Nottingham, UK.
  • Nugent KM; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Roeder E; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Littlejohn RO; Department of Pediatrics, Baylor College of Medicine, San Antonio, TX, 78207, USA.
  • Holder S; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Zhu W; Department of Pediatrics, Baylor College of Medicine, San Antonio, TX, 78207, USA.
  • Alaimo JT; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Graham B; Department of Pediatrics, Baylor College of Medicine, San Antonio, TX, 78207, USA.
  • Harris JM; North West Thames Regional Genetics Service, 759 Northwick Park Hospital, London, UK.
  • Gibson JB; Baylor Genetics, Houston, TX, 77021, USA.
  • Pastore M; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • McBride KL; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Komara M; Present address: Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Al-Gazali L; Dell Children's Medical Group, Austin, TX, 78723, USA.
  • Al Shamsi A; Dell Children's Medical Group, Austin, TX, 78723, USA.
  • Fanning EA; Division of Genetic and Genomic Medicine, Nationwide Children's Hospital; and Department of Pediatrics, College of Medicine, Ohio State University, Columbus, OH, 43205, USA.
  • Wierenga KJ; Division of Genetic and Genomic Medicine, Nationwide Children's Hospital; and Department of Pediatrics, College of Medicine, Ohio State University, Columbus, OH, 43205, USA.
  • Scott DA; Department of Pediatrics, College of Medicine & Health Sciences, United Arab University, Al Ain, UAE.
  • Ben-Neriah Z; Department of Pediatrics, College of Medicine & Health Sciences, United Arab University, Al Ain, UAE.
  • Meiner V; Department of Pediatrics, Tawam Hospital, Al-Ain, UAE.
  • Cassuto H; Department of Pediatrics, Section of Genetics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
  • Elpeleg O; Department of Pediatrics, Section of Genetics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
  • Holder JL; Present address: Mayo Clinic Florida, Department of Clinical Genomics, Jacksonville, FL, 32224, USA.
  • Burrage LC; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Seaver LH; Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Van Maldergem L; Department of Human Genetics and Metabolic Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Mahida S; Department of Human Genetics and Metabolic Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Soul JS; The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Marlatt M; Monique and Jacques Roboh Department of Genetic Research, Hadassah-Hebrew University Medical Center, 91120, Jerusalem, Israel.
  • Matyakhina L; Department of Pediatrics, Texas Children's Hospital, Houston, TX, 77030, USA.
  • Vogt J; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Gold JA; Department of Pediatrics, University of Hawaii, Honolulu, HI, 96826, USA.
  • Park SM; Centre de Génétique Humaine, Université de Franche-Comté, Besançon, France.
  • Varghese V; Department of Neurology, Boston Children's Hospital, Boston, MA, 0211, USA.
  • Lampe AK; Department of Neurology, Boston Children's Hospital, Boston, MA, 0211, USA.
  • Kumar A; Department of Neurology, Boston Children's Hospital, Boston, MA, 0211, USA.
  • Lees M; Gene DX, Gaithersburg, MD, 20877, USA.
  • Holder-Espinasse M; West Midlands Regional Clinical Genetics Service and Birmingham Health Partners; and Women's and Children's Hospitals NHS Foundation Trust, Birmingham, UK.
  • McConnell V; East Anglia Regional Genetics Service, Addenbrooke's Hospital, Cambridge, UK.
  • Bernhard B; East Anglia Regional Genetics Service, Addenbrooke's Hospital, Cambridge, UK.
  • Blair E; All-Wales Medical Genetics Service, University Hospital of Wales, Cardiff, UK.
  • Harrison V; South East of Scotland Clinical Genetic Service, Western General Hospital, Edinburgh, UK.
  • Muzny DM; North East Thames Regional Genetics Service, Great Ormond Street Hospital, London, UK.
  • Gibbs RA; South East Thames Regional Genetics Service, Guy's Hospital, London, UK.
  • Elsea SH; Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, UK.
  • Posey JE; North West Thames Regional Genetics Service, 759 Northwick Park Hospital, London, UK.
Genome Med ; 11(1): 12, 2019 02 28.
Article em En | MEDLINE | ID: mdl-30819258
BACKGROUND: Neurodevelopmental disorders are genetically and phenotypically heterogeneous encompassing developmental delay (DD), intellectual disability (ID), autism spectrum disorders (ASDs), structural brain abnormalities, and neurological manifestations with variants in a large number of genes (hundreds) associated. To date, a few de novo mutations potentially disrupting TCF20 function in patients with ID, ASD, and hypotonia have been reported. TCF20 encodes a transcriptional co-regulator structurally related to RAI1, the dosage-sensitive gene responsible for Smith-Magenis syndrome (deletion/haploinsufficiency) and Potocki-Lupski syndrome (duplication/triplosensitivity). METHODS: Genome-wide analyses by exome sequencing (ES) and chromosomal microarray analysis (CMA) identified individuals with heterozygous, likely damaging, loss-of-function alleles in TCF20. We implemented further molecular and clinical analyses to determine the inheritance of the pathogenic variant alleles and studied the spectrum of phenotypes. RESULTS: We report 25 unique inactivating single nucleotide variants/indels (1 missense, 1 canonical splice-site variant, 18 frameshift, and 5 nonsense) and 4 deletions of TCF20. The pathogenic variants were detected in 32 patients and 4 affected parents from 31 unrelated families. Among cases with available parental samples, the variants were de novo in 20 instances and inherited from 4 symptomatic parents in 5, including in one set of monozygotic twins. Two pathogenic loss-of-function variants were recurrent in unrelated families. Patients presented with a phenotype characterized by developmental delay, intellectual disability, hypotonia, variable dysmorphic features, movement disorders, and sleep disturbances. CONCLUSIONS: TCF20 pathogenic variants are associated with a novel syndrome manifesting clinical characteristics similar to those observed in Smith-Magenis syndrome. Together with previously described cases, the clinical entity of TCF20-associated neurodevelopmental disorders (TAND) emerges from a genotype-driven perspective.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Deficiências do Desenvolvimento / Anormalidades Craniofaciais / Mutação INDEL / Síndrome de Smith-Magenis / Deficiência Intelectual / Hipotonia Muscular Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Deficiências do Desenvolvimento / Anormalidades Craniofaciais / Mutação INDEL / Síndrome de Smith-Magenis / Deficiência Intelectual / Hipotonia Muscular Idioma: En Ano de publicação: 2019 Tipo de documento: Article